AOD9604 2mg

ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Beligas
WAREHOUSE International Warehouse 3
SUBSTANCE Anti-Obesity Drug-9604

Introducing AOD 9604, a groundbreaking peptide derived from Growth Hormone, consisting of 191 amino acids. This innovative formula features the last 15 amino acids (176-191) of the Growth Hormone chain, commonly known as GH Frag 176-191 or AOD 9604.

AOD 9604 is recognized as one of the most powerful peptides for weight loss, delivering exceptional benefits for fat reduction, metabolism enhancement, and overall wellness.

: Pituitary Gland

Also referred to as Tyr-hGH Frag 176-191, AOD-9604 boasts remarkable fat-burning properties without increasing appetite. It operates independently of the hGH receptor, facilitating fat degradation and oxidation while leaving blood sugar and tissue growth unaffected. Research in various animal models and human trials reveals that AOD-9604 effectively encourages fat release from predominantly obese fat cells, minimizes new fat formation, and enhances fat combustion, particularly targeting stubborn abdominal fat.

While CJC-1295 is another potent fat loss peptide that boosts overall GH levels, it?s essential to avoid GHRP products (like GHRP-6, GHRP-2, or GHRH), as they may increase hunger and cortisol levels. In contrast, AOD-9604 keeps appetite in check and does not elevate cortisol.

Developed in the 1990s by Professor Frank Ng at Monash University in Australia, AOD-9604 was engineered as an anti-obesity solution that mimics the fat-burning effects of human growth hormone without promoting muscle growth.

Recent studies have underscored not just AOD 9604?s fat loss capabilities but also its potential regenerative properties related to growth hormone. Ongoing research is investigating its applications for conditions like osteoarthritis, high cholesterol, and its role in bone and cartilage repair.

Notably, results from an oral glucose tolerance test confirmed that AOD 9604 does not adversely affect carbohydrate metabolism, and no anti-AOD 9604 antibodies were detected in tested patients. Importantly, no serious adverse events linked to AOD 9604 have been reported in clinical studies.

AOD 9604 demonstrates an impressive safety and tolerability profile, comparable to a placebo, and does not exhibit the negative side effects associated with full-length hGH treatment. With an outstanding safety record, AOD 9604 has recently achieved Human GRAS status in the USA.